company? Let’s change
that.
Viridos (formerly Synthetic Genomics, Inc) is a privately held biotechnology company harnessing the power of photosynthesis to create transformative solutions to mitigate climate change. Our unparalleled understanding of algal genetics and ability to translate innovation from lab to field underpins our initial deployment: a scalable platform to produce low-carbon intensity biofuels for aviation, commercial trucking, and maritime shipping. Building on a legacy of genomic firsts, our team of scientists and engineersare shaping new pathways toward a sustainable bioeconomy. To learn more, visit us at Viridos.com.
Alamar Biosciences is powering precision proteomics with automated, high throughput solutions for ultra-high sensitivity protein analysis across a range of multiplex levels. Our proprietary NULISA™ Chemistry utilizes a novel sequential capture and release method that significantly reduces background signal and increases the sensitivity and dynamic range compared with standard approaches and allows both qPCR and NGS readouts. The NULISAseq Inflammation Panel contains 200+ important markers related to immune and inflammatory diseases and will run on our ARGO™ System. This innovative platform allows for a fully automated workflow with less than 30 minutes hands on time from sample to data
Neurolink is an early-stage company developing a novel therapy for the treatment of epilepsy.
Preceptis Medical develops surgical tools that allow ear tube procedures to be performed with less pain.
Aerpio Pharmaceuticals is a biotechnology company that develops small molecules and monoclonal antibodies for vascular diseases treatment.
Sygnature Discovery is a world-leading integrated drug discovery Contract Research Organisation, with over 1000 staff from 53 nationalities, including 900 scientists working on drug discovery programmes. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.
Scismic is a tech platform built by scientists to help biotechs grow qualified and diverse scientific teams. Our specialized algorithm accurately targets relevant candidates for faster hiring. We are funded by the NIH to reduce bias in candidate evaluation through our gender- and race-blind skills matching technology, so you can hire scientists from all walks of life with the skills you need.
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. Our proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses.
Inanovate was founded in Massachusetts by two Babson MBA graduates, after winning first prize at the Babson Business Plan competition. The company has since grown operations in Massachusetts, North Carolina and the UK, forming close alliances with leading commercial and academic institutions. Inanovate has combined expertise from nano-scale physics, bio-engineering, bio-chemistry and biotechnology to create a unique mutliplexed protein screening technology called Longitudinal Assay Screening (LAS), designed to help advance the development and implementation of next generation therapeutics and clinical diagnostics. Inanovate has recently completed testing and demonstration of the world's first protein detection and measurement platform to integrate LAS - The Bio-ID 400.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Intuitive Biosciences provides tuberculosis and specific pathogen-free tests for non-human primate (NHP) research operations.
Excellos is a unique full-service CDMO that pairs the collection of critical human cells and tissues with manufacturing and development services to drive innovation in the cell and gene therapy industry. Built on the foundation of the San Diego Blood Bank, with over 70 years of experience in blood and tissue collection and handling, Excellos is focused on supplying cGMP cellular products and services, together with process development and manufacturing expertise to scientists and clinicians working with cell and gene therapies. Our relationship with the San Diego Blood Bank provides exclusive access to one of the largest and most diverse donor pools available, deep institutional expertise, and connection to a public cord blood bank. Excellos pairs this extraordinary resource with dedicated research and development capabilities to isolate, characterize, store, and transport human cell and tissue samples with the highest quality and viability, setting a new standard across the industry. Based in San Diego, Excellos serves the entire cell and gene therapy industry on a global scale, focusing on therapies in preclinical through phase II/III, and always with a clear scale-up pathway to support commercial level operations. Excellos is dedicated to improving human life by leveraging donor populations for life science research and the next generation of cell and gene therapies. Our goal is to facilitate the advancement of cellular therapies and help fully realize the potential of these powerful therapeutics, saving lives today and improving life tomorrow.
Dr. Raj Krishnan founded Biological Dynamics in 2010 with the goal to revolutionize diagnosis and treatment of high burden diseases. Under Raj's vision and guidance, Biological Dynamics has transformed from concept to early-stage startup and is now one of the most innovative diagnostic companies in Southern California. His passion and conviction have led Biological Dynamics through multiple rounds of funding, securing over $75 million in total. Raj has been recognized in the Top 30 under 30 scientists by Forbes magazine.
PHusis Therapeutics is developing novel targeted small molecule therapeutics
Cellara is an early-stage Madison, Wisconsin-based biotechnology company developing workflow solutions to address critical issues.
Stratify Genomics is a biotech company.
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio’s proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with mucosal pemphigus vulgaris, MuSK-associated myasthenia gravis, PLA2R-associated membranous nephropathy, mucocutaneous pemphigus vulgaris and hemophilia A with FVIII alloantibodies. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com.
Halo-Bio RNAi Therapeutics Inc. is an early stage company.
Vero biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (NO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions. At Vero Biotech, our mission is to improve the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is needed. We strive to exceed customer expectations in terms of safety, efficacy, and growth by focusing on the science, development, and commercialization of our innovations.